Why integrated drug–device testing is critical in autoinjector development

Published: 8-Jul-2025 Featured companies: Solvias AG
Manufacturing Regulatory Drug Delivery

A guide to robust testing strategies for accelerating timelines and reducing regulatory risk

With rising biologic complexity and stricter regulations, robust testing in autoinjector development is essential. Download the white paper for a comprehensive guide to functional, E&L, CCIT and stability testing in NIS-AUTO – designed to accelerate timelines and mitigate regulatory risks.

Access the white paper

Featured companies

Solvias helps innovative companies advance their path to commercialization with CMC analytical solutions powered by deep scientific expertise and a relentless focus on our...
  • Companies:
  • Solvias AG
See more

You may also like

Manufacturing

CMC Issues are a Leading Cause of Cell & Gene Therapies Clinical Holds

Read more
Overcoming CMC challenges to accelerate cell and gene therapy approvals

Trending Articles

  1. Gerresheimer achieves leadership status with A- CDP score Sustainability progress earns strong rating for climate disclosure and emissions strategy
  2. Gerresheimer reports H1 2025 growth driven by Bormioli Pharma acquisition Cosmetics and oral liquids markets dampen organic revenue but outlook remains strong
  3. Precision under pressure Why pharma manufacturing needs a harder look at weight control

Relevant companies

See more

Upcoming event

POWTECH

23-25 September 2025 | Exhibition | Nuremberg, Germany See all

You may also like

Manufacturing

CMC Issues are a Leading Cause of Cell & Gene Therapies Clinical Holds

Overcoming CMC challenges to accelerate cell and gene therapy approvals
Manufacturing

Did you know? USP compliance is expected by 2026

Ensuring compliance and safety in single-use manufacturing
Manufacturing

Solvias to build Biologics and Cell & Gene Therapy testing centre in Research Triangle Park

Global provider continues to expand analytical service capabilities for life science companies developing advanced treatments for cancer and rare diseases
Manufacturing

Solvias to perform release testing on world’s first CRISPR-based gene-editing therapy

Global provider signs long-term agreement with Vertex Pharmaceuticals for CASGEVY (trademarked)
Manufacturing

Solvias acquires Cergentis to boost biologics testing capabilities

The pharma testing company has made the acquisition to supports the increasing number of global pharmaceutical, biotech, and contract development and manufacturing organisations developing genetically engineered therapies
Manufacturing

Hovione and Solvias announce a collaboration to improve drug solubility

Combines the strengths of each company
Regulatory

AlzeCure's pain project ACD440 granted orphan drug status in the US by the FDA

AlzeCure Pharma announces that the US Food and Drug Administration (FDA) has granted the company's application for orphan drug status for the clinical pain candidate drug ACD440
Subscribe now